The licensable IP your team can’t surface today.
Lattis is a patent-BD intelligence platform for pharma licensing, business development, and IP teams. We index every U.S. pharma patent at the claim level — so you can search the field by meaning, analyze the estate you already own, and map the whitespace you don’t, all in one workspace.
What we do
Traditional patent search rewards the person who guesses the right keywords and classification codes. That leaves enormous value buried: the asset described in different language, filed under an adjacent CPC code, or held by an owner you weren’t watching. Lattis takes a different approach. We embed the full text of every patent in the corpus — claims, abstracts, and descriptions — and search by meaning, so the right asset surfaces even when its wording doesn’t match yours.
But finding the field asset is only part of the job. Lattis also turns the lens inward: upload your own patents and it resolves and clusters them into technology groups, then shows your exclusivity cliff, claim-type mix, and licensed-out roll-up. From there it maps the whitespace — the targets and modalities active in the adjacent field that your groups don’t cover — and benchmarks a group against a watched competitor’s patent estate.
Every result — inbound or internal — is enriched with the two facts a licensing conversation actually starts from: who owns it now and an evidence-backed read on whether it appears to be available. We treat that as a signal to verify, not a determination: diligence leads, not availability calls.
Targeted at pharma, not everything
The corpus is deliberately scoped to U.S. pharma patents — primarily CPC classes A61K (medicinal preparations), A61P (therapeutic activity), and C07K (peptides and antibodies), plus the adjacent classes that show up on real pharma filings. We don’t try to cover hardware, software, materials, or energy. That focus is what lets the rankings stay sharp: when you search for a GLP-1 receptor agonist, you get ranked pharma matches, not landscape noise from unrelated fields.
Inside that scope, coverage is complete: every grant, every assignee, every claim. If your roadmap touches a therapeutic area, mechanism, or modality that’s seen any U.S. patent activity, it’s in.
Who it’s for
- Licensing & BD teams hunting for assets that fill a pipeline gap or strengthen a position.
- IP & legal teams running landscape, freedom-to-operate, and prior-art searches that can’t afford to miss the obvious-in-hindsight result.
- Strategy & R&D leaders mapping who owns what in a fast-moving technology area.
How it works
You describe what you’re looking for in plain language — a problem, a capability, the asset you wish existed — and Lattis searches the corpus by meaning rather than exact terms, ranking what comes back by how closely it fits your intent. Or you start from your own book of business: upload a portfolio and Lattis analyzes it, surfaces where your protection is thin, and shows what rivals are building nearby. Either way, each result arrives with the ownership and licensing-status context you need to decide whether it’s worth a conversation — so you spend your time on the assets that matter, not on query syntax or spreadsheets.
Who we are
Want to see it on your own search? Join the pilot or get in touch.